DaVita Clinical Research Expands Capabilities With Investments in Central Laboratory
DaVita Clinical Research
announced the company’s recent investment in its Central Laboratory, servicing pharmaceutical, biotechnology, and medical device industries.
The investment was applied to analytical methodology, information technology (IT), and instrumentation in support of DCR’s continued drive to serve its clients. Over the past three years, DCR has had a strategic focus on Central Laboratory services, investing in state-of-the-art capital equipment, infrastructure and laboratory expansion/remodeling. The investment was placed in DCR’s Central Laboratory to ensure continuous delivery of customized care and satisfaction to its patients.
The Central Laboratory uses the latest in laboratory instrumentation. Some examples of the lab’s instrumentation and test menu include:
- 7 Olympus 5400
- 17 Siemens Centaur
- 9 Tosoh G-8
- 2 Liaison Diasorin
- 8 Perkin-Elmer ICP-MS
- 2 Nova
- 2 Dianex
- 23 Siemens Advia 2120
- 2 TOPS Coagulation
- 19 BACTEC 9240
- 14 Lonza BioTek
- 4 Vitek-2
DCR’s Central Laboratory also has invested in such technology as centrifuges, auto samplers, slide strainers, incubators, biosafety cabinets and decappers. DCR’s investment assisted in expanding and remodeling the laboratory, adding space to help facilitate future service expansion. In addition, extensive investment in its Falcon LabTM software application has resulted in the latest release, which includes an industry-leading report package.
At DCR’s Central Laboratory, individual trial samples are tracked using
LabScope Online
®, which ensures most specimen turnaround time of 24 hours or less.
The DCR Central Laboratory team is led by medical technologists, medical technicians and clinical pathologists, and receives formal guidance from nephrologists in the industry.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
